SAN DIEGO--(BUSINESS WIRE)--TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM.PK), a developer of transrenal molecular diagnostics, announced today that is has formed a Scientific Advisory Board (SAB) that will provide technical and strategic input to its Board of Directors and Management team. The SAB includes a group of medical professionals with the necessary subject matter expertise to support the diverse business interests of TrovaGene in the areas of cancer, infectious disease, organ transplantation and prenatal transrenal molecular diagnostics.
